İlkay KARAOĞLAN, Yasemin ZER, Mustafa NAMIDURU

Vankomisine dirençli enterokok suşlarında tigesiklinin in-vitro etkinliği

Gaziantep Üniversitesi Tıp Fakültesi Şahinbey Hastanesinde takip edilen hastaların kan, idrar, rektal sürüntü, sonda ucu gibi çeşitli örneklerinden Ekim 2006-Mart 2008 tarihleri arasında 60 vankomisine dirençli enterokok suşu izole edilmiş, bu suşlarda E- test yötemi ile tigesiklinin in-vitro etkinliği araştırılmıştır. 57 vankomisine dirençli Enterococcus faecium, 3 vankomisine dirençli Enterococcus gallinarum suşunun tamamının tigesikline düşük (MİK $leq$ 1g/ml) konsantrasyonlarda duyarlı olduğu bulunmuştur

Anahtar Kelimeler:

Vankomisin, Mikrobiyal duyarlılık testleri, Enterococcus faecium, Enterococcus

In-vitro activity of tygecycline for vancomisin-resistant Enterococcus strains

Between October 2006-March 2008, 60 vancomycin resistant Enterococcus strains were isolated from patients’ blood, urine, rectal swab and uretral cathater specimens in Gaziantep University School of Medicine, Sahinbey Hospital. In these strains, tigecyline sensitivity was investigated by E-test method. It was found that, 57 vancomycine resistant Enterococcus faecium, 3 vancomycin resistant Enterococcus gallinarum were all sensitive to tigecyline in low MIC values such as $leq$ 1 µg/m

Keywords:

Vancomycin, Microbial Sensitivity Tests, Enterococcus faecium, Enterococcus,

PDF

___

1. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ: In vitro activity of tigecyline against 3989 Gram-negative and Grampositive clinical isolates from the United States. Tigecyline Evaluation and Surveillance Trial (TEST Program; 2004), Diagn Microbiol Infect Dis 2005;52(3):173-9.
2. Bradford PA: Tigecycline: A first in class glycylcycline, Clin Microbiol Newslett 2004;26:163-8.
3. Dobbs TE, Patel M, Waites KB, Moser SA, Stamm AM, Hoesley CJ: Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center, J Clin Microbiol 2006;44(9):3368-70.
4. Gales AC, Jones RN: Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 clinical bacterial isolates, Diagn Microbiol Infect Dis 2000;36(1):19-36.
5. Garrison MW, Neumiller JJ, Setter SM: Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms, Clin Ther 2005;27(1):12-22.
6. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP: Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid, Lancet 2001;357(9263):1179.
7. Gültekin M, Günseren F: Vankomisine dirençli enterokoklar, Hastane infeksiyon Derg 2000;4(4):195-204.
8. Lee Do K, Kim Y, Park KS, Yang JW, Kim K, Ha NJ: Antimicrobial activity of mupirocin, daptomycin, linezolid, quinopristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005), J Biochem Mol Biol 2007;40(6):881-7.
9. Nathwani D: Tigecycline: clinical evidence and formulary positioning, Int J Antimicrob Agents 2005;25(3):185-92.
10. Noskin GA: Tigecycline: a new glycylcycline for treatment of serious infections, Clin Infect Dis 2005;41(Suppl 5):S303-14.
11. Raad I, Hachem R, Hanna H et al: Prospective randomized study compairing quinupristin-dalfopristin with linezolid in the treatment of vancomycin- resistant Enterococcus faecium infections, J Antimicrob Chemother 2004;53(4):646-9.
12. Robert C, Moellering JR: Enterococcus species, Streptococcus bovis and Leuconostoc species, ‘’Mandell GL, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Diseases, 6. baskı’’ kitabında s. 2411-21, Elsevier Churchill Livingstone,New York (2005).
13. Souli M, Kontopidou FV, Koratzanis E et al: In vitro activity of tigecyline against multiple-drug resistant, including pan-resistant, Gram negative and Gram positive clinical isolates from Greek hospitals, Antimicrob Agents Chemother 2006;50(9):3166-9.
14. Ulusoy S: Tigesiklin, ANKEM Derg 2006;20(Ek 2):117-9.
15. Werner G, Klare I, Spencker FB, Witte W: Intrahospital dissemination of quinopristin/dalfopristin -and vancomycin-resistant Enterococcus faecium in paediatric ward of a German hospital, J Antimicrob Chemother 2003;52(1):113-5.
16. Wesson KM, Lerner DS, Silverberg NB, Weinberg JM: Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology, Dis Mon 2004;50(7):395-406.